Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by elmothefearlesson Nov 07, 2012 1:12pm
177 Views
Post# 20572640

RE: RE: RE: RE: TheRock

RE: RE: RE: RE: TheRock

Dividends would have been paid in full from Q3 cash flow.

 

Cash flow during the third quarter we can estimate around $5.5 to $5.8 million when amortization is added back.  

 

All Q2 dividends were paid by June 30, 2012.  The dividend during Q3 is ~$1.2 million.  The special dividend of $0.26 is probably about equal to Q3 cash flow, or slightly less.  

 

$35 million - $14 million AP - $1.2 million dividend during Q3 = ~$20 million "cash", or about $25 million working capital when inventory and prepaids are included 

 

$20 million cash + $5.5 million cash flow from Q3 - $5.2 million dividend (special dividend) - $2.0 million share buyback (where do you even get this number) = ~$18 million cash, about $0.90 / share, throw in the working capital of $5 million and we are still looking at $23 million working capital or about $1.15 / share of positive working capital on the books

 

The only thing that changes was that the share buyback wasn't accounted for - and I don't know where you got this $2 million number, AM buybacks didn't seem to be anywhere close to this high, but I wasn't paying close attention to Canadian Insider.

 

so tobuyornot, did you just completely "miss" the $5.5 million of cash flow in Q3?

Bullboard Posts